In 2006, iRhythm Technologies was founded with a clear mission: to create a fundamentally better way to diagnose heart arrhythmias. The founders recognized that traditional cardiac monitoring methods were often uncomfortable, inconvenient, and missed critical data. They envisioned a patient-friendly solution that could capture continuous, high-quality ECG data over extended periods. This insight led to the development of the Zio ECG monitor - a wearable, single-use patch that patients can wear comfortably for up to 14 days, transforming the diagnostic experience for millions.
Today, iRhythm stands as a leading digital healthcare company that has served over 8 million patients and analyzed more than 1.5 billion hours of heartbeat data. The company's innovative platform combines FDA-cleared AI algorithms with deep-learning technology clinically proven to be as accurate as expert cardiologists. With operations across the United States, United Kingdom, and Japan, iRhythm continues to push boundaries in cardiac care. The company went public on Nasdaq (IRTC) and under the leadership of CEO Quentin Blackford, remains relentlessly focused on its mission to boldly innovate trusted solutions that detect, predict, and prevent disease.